Defining a New Class of Medicine

Codiak BioSciences is pioneering exosome research and development to create an entirely new class of medicines, exosome therapeutics. Our proprietary technology platform for exosome engineering and manufacturing allows precise therapeutic targeting, enabling us to develop therapies that may address a diverse array of diseases that are currently difficult or impossible to treat using existing methodologies.

At Codiak, we have developed the technology to turn exosomes into therapeutics.

Manufacturing Innovation

Transformative Potential

Exosomes as Potent Messengers

Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know these natural, cell-derived vesicles can act as an efficient, versatile and non-immunogenic delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak has taken a rigorous scientific approach to unlock their vast potential as therapeutics.

Producing Tomorrow’s Medicines

Our proprietary engEx™ Platform enables precision engineering and reliable, industrial-scale manufacturing of novel exosome product candidates with therapeutic potential across multiple indications. We plan to advance our first two engEX product candidates, exoSTING™ and exoIL-12™, into clinical development in 2020.

Pioneering Vision

At the Frontier

Pioneering technology and groundbreaking research form the basis of our vision to harness the power of exosomes to create an entirely new class of biologic medicines. We are building the leading, fully integrated exosome therapeutics company through world-class research, technology advancement, manufacturing, and clinical development.

Work With Us

Advance the emerging and exciting field of exosome biology into therapeutics with transformative potential at Codiak.